APGE Apogee Therapeutics, Inc.
Q3 2025 10-Q
Filed: Nov 10, 2025Period ending Sep 30, 2025
Health Care
Biological Products, (No Diagnostic Substances)SEC EDGAR Apogee Therapeutics, Inc. (APGE) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 10, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
AI Filing AnalysisQ3 2025 10-Q
Risk Factors
- • New geopolitical risk from conflicts involving Russia, Ukraine, Israel, and Hamas impacting financial markets and capital raising ability
- • Updated financial risk: net loss $186.5M for nine months ended Sep 30, 2025; cash runway now into second half of 2028
Quarterly Financial SummaryXBRL
Net Income
-$65M
Total Assets
$626M
Source: XBRL data from Apogee Therapeutics, Inc. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on Apogee Therapeutics, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.